Live Webinar

Primary Care Webinar 2 – Arrhythmias in patients with hypertrophic cardiomyopathy: what do primary care providers need to know? (Second schedule)

Course Overview

This event will take place twice on June 1st, 2023
First schedule: 1pm EDT / 7pm CET
Second schedule: 7pm EDT / 1am CET (+1)

This expert webinar is designed to provide knowledge around the management of atrial fibrillation and arrhythmias in HCM patients. It assists primary healthcare professionals to:

  • understand the pathophysiology of atrial fibrillation and arrhythmias, and the consequences in HCM patients
  • support appropriate management strategies for HCM patients with atrial fibrillation

This webinar is 60 minutes duration.

Target audience

Family/general/internal medicine physicians, nurse practitioners, registered nurses, clinical nurse specialists, physician assistants, pediatricians, pediatric nurses.

Funding disclosure

This activity is supported by educational grant funding from Bristol Myers Squibb and Cytokinetics. Learners may participate in this educational activity free of charge.

  • Welcome and introduction
  • Overview of arrhythmias
  • Treatment overview and clinical case example
  • Q&A and closing remarks​

By the end of this activity, attendees will be able to:

  • summarize the risk of developing atrial fibrillation and other arrhythmias in HCM patients
  • describe the underlying pathophysiology of HCM that leads to the development of atrial fibrillation
  • summarize the consequences of atrial fibrillation for HCM patients
  • describe appropriate management strategies for HCM patients with atrial fibrillation, and how they may impact primary care considerations

This activity will provide continuing education (CE) credits for physicians, physician assistants, nurses and nurse practitioners.

Dr John Lynn Jefferies, MD, Jay M. Sullivan Endowed Chair in Cardiovascular Medicine and Chief of Cardiology University of Tennessee, USA​, has received financial compensation for consulting for Bristol Myers Squibb, and received speaker fees from Bristol Myers Squibb.

Dr Pablo Garcia-Pavia, MD, Head of the Inherited Cardiac Diseases and Heart Failure Unit, Hospital Universitario Puerta de Hierro, Spain​, has received financial compensation for consulting for Pfizer, Astrazeneca, Bristol Myers Squibb, Norvonordisk, Cytokinetics, Neuroimmune, Alnylam, Attralus, Intellia Therapeutics, and has received speaker fees from Pfizer, Astrazeneca, Bristol Myers Squibb.

AffinityCE staff, PCM Scientific staff, as well as planners and reviewers have no relevant financial interests to disclose.

Mitigation of relevant financial relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.